Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by serendipidyon Jan 09, 2020 6:38pm

177 Views

Post# 30536675

Kaly Potential

Im going to put this in writing as to have something to refer to later. I have had the pleasure to speak with Rob on many occasions. He has something BIG here and he knows it! The news release clearly spoke to the idea that they will not be giving news for news sake. We will be rewarded, and rewarded well, not the .10 or so cents per share some people are claiming. This is significant, and if one has a reasonable amount of shares, id say life changing..

Bullboard Posts

Consumer advocacy law firm investigates Microsoft over X-Box data concerns